Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Moved Up to Sell by Wall Street Zen

Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a strong sell rating to a sell rating in a research note published on Sunday morning,Wall Street Zen reports.

EYPT has been the topic of a number of other research reports. Chardan Capital downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a research note on Tuesday, August 18th. TD Cowen downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the company from $20.00 to $4.00 in a report on Wednesday, September 2nd. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Jefferies Financial Group dropped their price objective on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 17th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $25.70.

Eyepoint Pharmaceuticals Price Performance

Shares of Eyepoint Pharmaceuticals stock opened at $3.62 on Friday. The firm has a fifty day moving average price of $7.80 and a 200 day moving average price of $11.46. Eyepoint Pharmaceuticals has a 1 year low of $3.41 and a 1 year high of $19.11. The stock has a market cap of $312.08 million, a PE ratio of -0.97 and a beta of 1.63.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. As a group, equities analysts expect that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RWC Asset Management LLP raised its position in Eyepoint Pharmaceuticals by 6.4% during the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after acquiring an additional 1,040 shares during the period. MCF Advisors LLC grew its position in shares of Eyepoint Pharmaceuticals by 8.3% in the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after purchasing an additional 1,149 shares during the period. KBC Group NV purchased a new stake in shares of Eyepoint Pharmaceuticals during the first quarter worth about $29,000. Janney Montgomery Scott LLC increased its stake in shares of Eyepoint Pharmaceuticals by 14.8% during the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock worth $391,000 after purchasing an additional 3,900 shares in the last quarter. Finally, Baird Financial Group Inc. raised its position in shares of Eyepoint Pharmaceuticals by 16.4% during the 2nd quarter. Baird Financial Group Inc. now owns 32,732 shares of the company’s stock worth $468,000 after purchasing an additional 4,613 shares during the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a commercial-stage biotechnology company focused on developing and delivering treatments for serious eye diseases. The company’s proprietary technology is designed to provide sustained, localized release of pharmaceutical compounds within the eye, with the goal of reducing treatment frequency and improving outcomes for patients and physicians.

EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide implant for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, and DEXYCU, a sustained-release dexamethasone intraocular suspension used to treat inflammation following ophthalmic surgery.